期刊文献+

顶空气相色谱法测定唑来膦酸中有机溶剂残留量 被引量:2

Determination of Residual Solvent in Zoledronic Acid by Headspace GC
下载PDF
导出
摘要 目的采用顶空气相色谱法测唑来膦酸中有机溶剂残留量。方法用DB-624毛细管柱(30 m×0.32 mm,1.8μm),柱温为起始温度40℃,维持10 min,再以每分钟35℃的速率升温至220℃,维持5 min;进样口温度为250℃;氢火焰离子化检测器(FID);检测器温度为280℃。结果6种溶剂的分离度良好,在所考察的质量浓度范围内线性关系良好,r=0.999 9,平均回收率为96.9%~102.3%,检出限为7.86 pg/mL^75.0 ng/mL。结论所用方法简单、灵敏度高,可用于唑来膦酸中有机溶剂残留量的限度检查。 Objective To adopt the headspace gas chromatography(GC) method for determining the residual solvent in zoledronic acid. Methods The DB-624 capillary column(30 m×0. 32 mm, 1.8 μm) was adopted;the initial temperature was 40℃ ,maintained for 10 min,then heated up to 220 ~C with the rate of 30 ℃/min and maintained for 5min at 220 ℃ ;the injector port temperature was 250 ℃; the FID detector temperature was at 280 ~C. Results Several solvents of methanol, ethanol, acetone, acetonitrile, dichloromethane and hexane had the good separation degrees and good linear relations during the investigated concentration range, r = 0. 999 9 ,the aver- age recovery rate was 96.9%-102.3%.The detection limit was 7.86-75.0 ng/mL. Conclusion The used method is simple with high sensitivity and can be applied to the limit test of residual organic solvent in zoledronic acid.
作者 李玮玲
出处 《中国药业》 CAS 2013年第22期55-56,共2页 China Pharmaceuticals
关键词 顶空气相色谱法 有机溶剂残留量 唑来膦酸 headspace gas chromatography residual solvent zoledronic acid
  • 相关文献

参考文献7

二级参考文献43

  • 1李增云,马庆彤,任晓,刘娜,陈树泉,王达,王健.唑来膦酸联合放疗治疗骨转移性疼痛的临床观察[J].四川肿瘤防治,2006,19(3):208-209. 被引量:11
  • 2张青,赵蓓初,李建力.唑来膦酸的药理作用及临床应用[J].实用临床医药杂志,2006,10(4):132-134. 被引量:23
  • 3Delmas PD. The use of bisphosphonates in the treatment of osteoporosis[J].Curr Opin Rheumatol, 2005, 17(4):462- 466.
  • 4Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates[J].J Dent Res, 2007, 86(11): 1022-1033.
  • 5Black DM, Delmas PD, Eastell R, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med, 2007, 356(18): 1809-1822.
  • 6Henneman ZJ, Nancollas GH, Ebetino FH, et al. Bisphosphonate bone affinity as assessed by inhibition of carbonated apatite dissolution in vitro[J]. J Biomed Mater Res A, 2008, 85(4): 993-1000.
  • 7Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients[J]. Clin Cancer Res, 2003, 9(8): 2893-2897.
  • 8Vincenzi B, Santini D, Dicuonzo G, et ai. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients[J].J Interferon Cytokine Res, 2005, 25(3):144-151.
  • 9Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J].Nature, 2000, 407(6801): 249 - 257.
  • 10Boissier S, Colombel M, Delmas P, et al. Zoledronic acid inhibits in vivo experimental angiogenesis[J].Bone, 2002, 30(3 Suppl):38S.

共引文献24

同被引文献30

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部